Sökning: onr:"swepub:oai:DiVA.org:liu-110284" >
Catumaxomab with an...
-
Sehouli, JalidCharite, Germany
(författare)
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
2014-06-26
-
Humana Press,2014
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-110284
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-110284URI
-
https://doi.org/10.1007/s12032-014-0076-7DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Fresenius Biotech GmbH
-
This two-arm, randomised, multicentre, open-label, phase IIIb study investigated the safety and efficacy of a 3-h catumaxomab infusion with/without prednisolone premedication to reduce catumaxomab-related adverse events. Patients with malignant ascites due to epithelial cancer received four 3-h intraperitoneal catumaxomab infusions with/without intravenous prednisolone (25 mg) premedication before each infusion. The primary safety endpoint was a composite safety score calculated from the incidence and intensity of the most frequent catumaxomab-related adverse events (pyrexia, nausea, vomiting and abdominal pain). Puncture-free survival (PuFS) was a co-primary endpoint. Time to next puncture (TTPu) and overall survival (OS) were secondary endpoints. Prednisolone premedication did not result in a significant reduction in the main catumaxomab-related adverse events. The mean composite safety score was comparable in both arms (catumaxomab plus prednisolone, 4.1; catumaxomab, 3.8; p = 0.383). Median PuFS (30 vs. 37 days) and TTPu (78 vs. 102 days) were shorter in the catumaxomab plus prednisolone arm than in the catumaxomab arm, but the differences were not statistically significant (p = 0.402 and 0.599, respectively). Median OS was longer in the catumaxomab plus prednisolone arm than in the catumaxomab arm (124 vs. 86 days), but the difference was not statistically significant (p = 0.186). The superiority of catumaxomab plus prednisolone versus catumaxomab alone could not be proven for the primary endpoint. Prednisolone did not result in a significant reduction in the main catumaxomab-related adverse events. The study confirms the safety and efficacy of catumaxomab administered as four 3-h intraperitoneal infusions for the treatment of malignant ascites.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Pietzner, KlausCharite, Germany
(författare)
-
Wimberger, PaulineTechnical University of Dresden, Germany
(författare)
-
Vergote, IgnaceUniversity Hospital Leuven, Belgium
(författare)
-
Rosenberg, PerÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)perro95
(författare)
-
Schneeweiss, AndreasUniversity of Heidelberg Hospital, Germany
(författare)
-
Bokemeyer, CarstenUniversity of Medical Centre Hamburg Eppendorf, Germany
(författare)
-
Salat, ChristophHematol Oncology Clin, Germany
(författare)
-
Scambia, GiovanniCatholic University, Italy
(författare)
-
Berton-Rigaud, DominiqueCLCC Rene Gauducheau, France
(författare)
-
Santoro, ArmandoHumanitas Cancer Centre, Italy
(författare)
-
Cervantes, AndresUniversity of Valencia, Spain
(författare)
-
Tredan, OlivierCentre Leon Berard, France
(författare)
-
Tournigand, ChristopheHop St Antoine, France
(författare)
-
Colombo, NicolettaUniversity of Milano Bicocca, Italy
(författare)
-
Dudnichenko, Alexander S.Kharkov Medical Academic Postgrad Educ, Ukraine
(författare)
-
Westermann, AnnekeUniversity of Amsterdam, Netherlands
(författare)
-
Friccius-Quecke, HilkeNeovu Biotech GmbH, Germany
(författare)
-
Lordick, FlorianUniversity of Cancer Centre Leipzig, Germany
(författare)
-
Charite, GermanyTechnical University of Dresden, Germany
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Medical Oncology: Humana Press31:8, s. 76-1357-05601559-131X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sehouli, Jalid
-
Pietzner, Klaus
-
Wimberger, Pauli ...
-
Vergote, Ignace
-
Rosenberg, Per
-
Schneeweiss, And ...
-
visa fler...
-
Bokemeyer, Carst ...
-
Salat, Christoph
-
Scambia, Giovann ...
-
Berton-Rigaud, D ...
-
Santoro, Armando
-
Cervantes, Andre ...
-
Tredan, Olivier
-
Tournigand, Chri ...
-
Colombo, Nicolet ...
-
Dudnichenko, Ale ...
-
Westermann, Anne ...
-
Friccius-Quecke, ...
-
Lordick, Florian
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Medical Oncology
- Av lärosätet
-
Linköpings universitet